Cargando…

The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma

BACKGROUND: In this study, we comprehensively analyzed genes related to ferroptosis and iron metabolism to construct diagnostic and prognostic models and explore the relationship with the immune microenvironment in HCC. METHODS: Integrated analysis, cox regression and the least absolute shrinkage an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Bufu, Zhu, Jinyu, Li, Jie, Fan, Kai, Gao, Yang, Cheng, Shimiao, Kong, Chunli, Zheng, Liyun, Wu, Fazong, Weng, Qiaoyou, Lu, Chenying, Ji, Jiansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592541/
https://www.ncbi.nlm.nih.gov/pubmed/33115468
http://dx.doi.org/10.1186/s12964-020-00663-1
_version_ 1783601207345938432
author Tang, Bufu
Zhu, Jinyu
Li, Jie
Fan, Kai
Gao, Yang
Cheng, Shimiao
Kong, Chunli
Zheng, Liyun
Wu, Fazong
Weng, Qiaoyou
Lu, Chenying
Ji, Jiansong
author_facet Tang, Bufu
Zhu, Jinyu
Li, Jie
Fan, Kai
Gao, Yang
Cheng, Shimiao
Kong, Chunli
Zheng, Liyun
Wu, Fazong
Weng, Qiaoyou
Lu, Chenying
Ji, Jiansong
author_sort Tang, Bufu
collection PubMed
description BACKGROUND: In this study, we comprehensively analyzed genes related to ferroptosis and iron metabolism to construct diagnostic and prognostic models and explore the relationship with the immune microenvironment in HCC. METHODS: Integrated analysis, cox regression and the least absolute shrinkage and selection operator (LASSO) method of 104 ferroptosis- and iron metabolism-related genes and HCC-related RNA sequencing were performed to identify HCC-related ferroptosis and iron metabolism genes. RESULTS: Four genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models. Poorer overall survival (OS) was exhibited in the high-risk group than that in the low-risk group in both the training cohort (P < 0.001, HR = 0.27) and test cohort (P < 0.001, HR = 0.27). The diagnostic models successfully distinguished HCC from normal samples and proliferative nodule samples. Compared with low-risk groups, high-risk groups had higher TMB; higher fractions of macrophages, follicular helper T cells, memory B cells, and neutrophils; and exhibited higher expression of CD83, B7H3, OX40 and CD134L. As an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy. CONCLUSIONS: The prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contais supplementary material available at 10.1186/s12964-020-00663-1.
format Online
Article
Text
id pubmed-7592541
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75925412020-10-29 The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma Tang, Bufu Zhu, Jinyu Li, Jie Fan, Kai Gao, Yang Cheng, Shimiao Kong, Chunli Zheng, Liyun Wu, Fazong Weng, Qiaoyou Lu, Chenying Ji, Jiansong Cell Commun Signal Research BACKGROUND: In this study, we comprehensively analyzed genes related to ferroptosis and iron metabolism to construct diagnostic and prognostic models and explore the relationship with the immune microenvironment in HCC. METHODS: Integrated analysis, cox regression and the least absolute shrinkage and selection operator (LASSO) method of 104 ferroptosis- and iron metabolism-related genes and HCC-related RNA sequencing were performed to identify HCC-related ferroptosis and iron metabolism genes. RESULTS: Four genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models. Poorer overall survival (OS) was exhibited in the high-risk group than that in the low-risk group in both the training cohort (P < 0.001, HR = 0.27) and test cohort (P < 0.001, HR = 0.27). The diagnostic models successfully distinguished HCC from normal samples and proliferative nodule samples. Compared with low-risk groups, high-risk groups had higher TMB; higher fractions of macrophages, follicular helper T cells, memory B cells, and neutrophils; and exhibited higher expression of CD83, B7H3, OX40 and CD134L. As an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy. CONCLUSIONS: The prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contais supplementary material available at 10.1186/s12964-020-00663-1. BioMed Central 2020-10-28 /pmc/articles/PMC7592541/ /pubmed/33115468 http://dx.doi.org/10.1186/s12964-020-00663-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tang, Bufu
Zhu, Jinyu
Li, Jie
Fan, Kai
Gao, Yang
Cheng, Shimiao
Kong, Chunli
Zheng, Liyun
Wu, Fazong
Weng, Qiaoyou
Lu, Chenying
Ji, Jiansong
The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
title The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
title_full The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
title_fullStr The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
title_full_unstemmed The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
title_short The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
title_sort ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592541/
https://www.ncbi.nlm.nih.gov/pubmed/33115468
http://dx.doi.org/10.1186/s12964-020-00663-1
work_keys_str_mv AT tangbufu theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT zhujinyu theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT lijie theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT fankai theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT gaoyang theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT chengshimiao theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT kongchunli theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT zhengliyun theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT wufazong theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT wengqiaoyou theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT luchenying theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT jijiansong theferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT tangbufu ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT zhujinyu ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT lijie ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT fankai ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT gaoyang ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT chengshimiao ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT kongchunli ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT zhengliyun ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT wufazong ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT wengqiaoyou ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT luchenying ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma
AT jijiansong ferroptosisandironmetabolismsignaturerobustlypredictsclinicaldiagnosisprognosisandimmunemicroenvironmentforhepatocellularcarcinoma